The site is undergoing maintenance. Ordering can continue through fax and phone.
Sunday, August 16, 2026, 1:30 - 4:30 pm (CEST).
If you encounter problems while ordering. Please contact us at BDBCustomerService@bd.com
See More
The site is undergoing maintenance. Ordering can continue through fax and phone.
Sunday, August 16, 2026, 1:30 - 4:30 pm (CEST).
If you encounter problems while ordering. Please contact us at BDBCustomerService@bd.com
See MoreThe site is undergoing maintenance. Ordering can continue through fax and phone.
Sunday, August 16, 2026, 1:30 - 4:30 pm (CEST)
.If you encounter problems while ordering. Please contact us at BDBCustomerService@bd.com
This page has been recently translated and is available in French now.
Looks like you're visiting us from {countryName}.
Would you like to stay on the current location site or be switched to your location?
Western blotting for human FAK (pY397). Human endothelial cells were treated with 1 mM pervanadate, a general inhibitor of protein tyrosine phosphotases, for 15 minutes at 37°C then either left untreated (lane 1) or treated (lane 2) with 50 µg/ml alkaline phosphatase for 30 minutes at 37°C. The top panel was probed with mouse anti-FAK antibody (Cat. No. 610087) and the bottom panel was probed with the mouse anti-human FAK (pY397) antibody at a 1:1000 dilution. The target band in each panel may be observable in a range of 116-125 kD.
Immunofluorescent staining of A549 cells. A549 cells (ATCC CCL-185) were seeded in a BD Falcon™ 96-well imaging plate (Cat. No. 353219) at ~ 10,000 cells per well. After overnight incubation, cells were stained using the Triton™ X-100 fix/perm protocol and the mouse anti-human FAK (pY397) antibody. The second step reagent was Alexa Fluor® 488 goat anti-mouse Ig (Invitrogen). Images were taken on a BD Pathway™ 855 Bioimager using a 20x objective. This antibody also stained U-2 OS (ATCC HTB-96) and HeLa (ATCC CCL-2) cells using either the Triton™ X-100 or alcohol perm protocols (see Recommended Assay Procedure).
Western blotting for human FAK (pY397). Human endothelial cells were treated with 1 mM pervanadate, a general inhibitor of protein tyrosine phosphotases, for 15 minutes at 37°C then either left untreated (lane 1) or treated (lane 2) with 50 µg/ml alkaline phosphatase for 30 minutes at 37°C. The top panel was probed with mouse anti-FAK antibody (Cat. No. 610087) and the bottom panel was probed with the mouse anti-human FAK (pY397) antibody at a 1:1000 dilution. The target band in each panel may be observable in a range of 116-125 kD.
Immunofluorescent staining of A549 cells. A549 cells (ATCC CCL-185) were seeded in a BD Falcon™ 96-well imaging plate (Cat. No. 353219) at ~ 10,000 cells per well. After overnight incubation, cells were stained using the Triton™ X-100 fix/perm protocol and the mouse anti-human FAK (pY397) antibody. The second step reagent was Alexa Fluor® 488 goat anti-mouse Ig (Invitrogen). Images were taken on a BD Pathway™ 855 Bioimager using a 20x objective. This antibody also stained U-2 OS (ATCC HTB-96) and HeLa (ATCC CCL-2) cells using either the Triton™ X-100 or alcohol perm protocols (see Recommended Assay Procedure).
Western blotting for human FAK (pY397). Human endothelial cells were treated with 1 mM pervanadate, a general inhibitor of protein tyrosine phosphotases, for 15 minutes at 37°C then either left untreated (lane 1) or treated (lane 2) with 50 µg/ml alkaline phosphatase for 30 minutes at 37°C. The top panel was probed with mouse anti-FAK antibody (Cat. No. 610087) and the bottom panel was probed with the mouse anti-human FAK (pY397) antibody at a 1:1000 dilution. The target band in each panel may be observable in a range of 116-125 kD.
Immunofluorescent staining of A549 cells. A549 cells (ATCC CCL-185) were seeded in a BD Falcon™ 96-well imaging plate (Cat. No. 353219) at ~ 10,000 cells per well. After overnight incubation, cells were stained using the Triton™ X-100 fix/perm protocol and the mouse anti-human FAK (pY397) antibody. The second step reagent was Alexa Fluor® 488 goat anti-mouse Ig (Invitrogen). Images were taken on a BD Pathway™ 855 Bioimager using a 20x objective. This antibody also stained U-2 OS (ATCC HTB-96) and HeLa (ATCC CCL-2) cells using either the Triton™ X-100 or alcohol perm protocols (see Recommended Assay Procedure).
Any use of products other than the permitted use without the express written authorization of Becton, Dickinson and Company is strictly prohibited.
Bioimaging
1. Seed the cells in appropriate culture medium at ~10,000 cells per well in a BD Falcon™ 96-well Imaging Plate (Cat. No. 353219) and culture overnight.
2. Remove the culture medium from the wells, and fix the cells by adding 100 μl of BD Cytofix™ Fixation Buffer (Cat. No. 554655) to each well. Incubate for 10 minutes at room temperature (RT).
3. Remove the fixative from the wells, and permeabilize the cells using either BD Perm Buffer III, 90% methanol, or Triton™ X-100:
a. Add 100 μl of -20°C 90% methanol or Perm Buffer III (Cat. No. 558050) to each well and incubate for 5 minutes at RT.
OR
b. Add 100 μl of 0.1% Triton™ X-100 to each well and incubate for 5 minutes at RT.
4. Remove the permeabilization buffer, and wash the wells twice with 100 μl of 1× PBS.
5. Remove the PBS, and block the cells by adding 100 μl of BD Pharmingen™ Stain Buffer (FBS) (Cat. No. 554656) to each well. Incubate for 30 minutes at RT.
6. Remove the blocking buffer and add 50 μl of the optimally titrated primary antibody (diluted in Stain Buffer) to each well, and incubate for 1 hour at RT.
7. Remove the primary antibody, and wash the wells three times with 100 μl of 1× PBS.
8. Remove the PBS, and add the second step reagent at its optimally titrated concentration in 50 μl to each well, and incubate in the dark for 1 hour at RT.
9. Remove the second step reagent, and wash the wells three times with 100 μl of 1× PBS.
10. Remove the PBS, and counter-stain the nuclei by adding 200 μl per well of 2 μg/ml Hoechst 33342 (e.g., Sigma-Aldrich Cat. No. B2261) in 1× PBS to each well at least 15 minutes before imaging.
11. View and analyze the cells on an appropriate imaging instrument.
Bioimaging: For more detailed information please refer to http://www.bdbiosciences.com/support/resources/protocols/ceritifed_reagents.jsp
Western blot: For more detailed information please refer to http://www.bdbiosciences.com/pharmingen/protocols/Western_Blotting.shtml
Focal Adhesion Kinase (FAK) is a cytoplasmic tyrosine kinase that colocalizes with integrins in focal adhesions. This cellular localization is directed by a 125 amino acid sequence at the C-terminus called the "Focal Adhesion Targeting" sequence (FAT). The binding of extracellular matrix ligands to integrins triggers autophosphorylation at Tyr-397, and activation of FAK through phosphorylation of Tyr residues (Tyr-576 and Tyr577) in the kinase domain activation loop. For example, cell adhesion to a fibronectin substratum involves concurrent activation of Src and phosphorylation of the FAK activation loop. In addition, phosphorylation of other Tyr residues (Tyr-925, and Tyr-861) creates binding sites for SH2 domains of intracellular signaling molecules such as Src, PI3 kinase, and Grb2. FAK's ability to bind numerous structural and signaling proteins via a variety of interactions is important for FAK activation level, and for FAK interaction with a variety of substrates localized to sites of cell adhesion. Thus, FAK activity is regulated by a complex set of phosphorylation sites, and this phospho-regulation could be important for cell motility, cell growth, cytoskeletal organization, and adhesion-dependent cell survival.
Please refer to Support Documents for Quality Certificates
Global - Refer to manufacturer's instructions for use and related User Manuals and Technical data sheets before using this products as described
Comparisons, where applicable, are made against older BD Technology, manual methods or are general performance claims. Comparisons are not made against non-BD technologies, unless otherwise noted.
For Research Use Only. Not for use in diagnostic or therapeutic procedures.